{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:01:12Z","timestamp":1790146872149,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The growing use and public visibility of injectable weight-loss medications, including GLP-1 receptor agonists and related therapies, have raised important public health concerns regarding knowledge, attitudes, information sources, and safe use. This study assessed knowledge, attitudes, information sources, perceived social media influence, misconceptions, and self-reported use or consideration of weight-loss injections among adults in Al-Ahsa, Saudi Arabia, and examined associations with selected participant characteristics and BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This descriptive, cross-sectional study included 718 adults in Al-Ahsa, Saudi Arabia, and was conducted using an online structured questionnaire that was reviewed by experts and pilot-tested before the main data collection. Data were analyzed using the Statistical Package for the Social Sciences version 29. Descriptive statistics were used to summarize participant characteristics, knowledge, attitudes, information sources, perceived social media influence, and use patterns. Chi-square tests were used to examine associations between weight-loss injection use or consideration and selected participant characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Knowledge responses showed uncertainty regarding several aspects of weight-loss injections, particularly their mechanisms and potential adverse effects. Participants generally recognized the risks associated with unsupervised use, while perceptions regarding effectiveness and long-term safety were more varied. Overall, 8.5% of participants reported current or previous use of weight-loss injections, and 8.5% reported considering future use. Among users, tirzepatide was the most commonly reported injection (42.6%), followed by semaglutide (39.3%) and liraglutide (14.8%). Social media was the most frequently reported source of information (62.1%), followed by friends or family (41.5%) and healthcare professionals (39.1%). Use or consideration of weight-loss injections was significantly associated with age group, education level, and BMI category, but not sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adults in Al-Ahsa showed considerable uncertainty across several knowledge items and generally mixed perceptions regarding the effectiveness and safety of weight-loss injections, with relatively low current or previous use but emerging interest in future use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1918350","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:01Z","timestamp":1790144161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Knowledge, attitudes, information sources, and use of weight-loss injections among adults in Al-Ahsa, Saudi Arabia: a cross-sectional study"],"prefix":"10.3389","volume":"14","author":[{"given":"Shahad","family":"Alshamrani","sequence":"first","affiliation":[{"name":"Department of Public Health, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadwa","family":"Alqasem","sequence":"additional","affiliation":[{"name":"Department of Public Health, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danah","family":"Alkhamis","sequence":"additional","affiliation":[{"name":"Department of Public Health, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munerah","family":"Almulhem","sequence":"additional","affiliation":[{"name":"Department of Public Health, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12889-021-12449-2","article-title":"Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life","volume":"22","author":"Hecker","year":"2022","journal-title":"BMC Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/aihb.aihb_106_22","article-title":"Obesity and overweight: a global public health issue","volume":"13","author":"Salam","year":"2023","journal-title":"Adv Hum Biol"},{"key":"ref3","volume-title":"GASTAT Publishes the Results of Health Determinants Statistics Publication in Saudi Arabia 2024","year":"2024"},{"key":"ref4","volume-title":"Obesity and Overweight","year":"2025"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann Saudi Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1214334","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.124.069680","article-title":"Digital footprints of obesity treatment: GLP-1 receptor agonists and the health equity divide","volume":"150","author":"Azizi","year":"2024","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-025-04528-7","article-title":"Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","volume":"24","author":"Jackson","year":"2026","journal-title":"BMC Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00210-025-04403-5","article-title":"Misrepresentation of semaglutide in social media","volume":"399","author":"Propfe","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e46957","DOI":"10.1097\/MD.0000000000046957","article-title":"Assessment of community awareness and attitude about the use of GLP-1 agonists as a treatment for obesity in Saudi Arabia: cross-sectional study","volume":"105","author":"Abualhommos","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e42875","DOI":"10.7759\/cureus.42875","article-title":"Knowledge and attitude of the general population in Saudi Arabia toward weight management medications (WMMs): a cross-sectional study","volume":"15","author":"Algarni","year":"2023","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/healthcare14030345","article-title":"Prevalence and factors associated with GLP-1 receptor agonist use for weight management among overweight and obese adults in the Eastern Province of Saudi Arabia","volume":"14","author":"Alhussain","year":"2026","journal-title":"Healthcare (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like Peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e002519","DOI":"10.1136\/bmjph-2024-002519","article-title":"What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK","volume":"3","author":"Auerbach","year":"2025","journal-title":"BMJ Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/02813432.2025.2477141","article-title":"Patients' experiences with GLP-1-RAs - a systematic review","volume":"43","author":"Ibsen","year":"2025","journal-title":"Scand J Prim Health Care"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12902-026-02273-3","article-title":"Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1\u2013based therapies: a retrospective observational study in the United Arab Emirates","volume":"26","author":"Almemari","year":"2026","journal-title":"BMC Endocr Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1186\/s12889-025-24197-8","article-title":"Critical discourse analysis of social media advertisements for GLP-1 receptor agonist weight loss drugs: implications for public perceptions and health communication","volume":"25","author":"Rad","year":"2025","journal-title":"BMC Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"E797","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"CMAJ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.eclinm.2025.103464","article-title":"Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis","volume":"88","author":"Chu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/medicina61111987","article-title":"Gastrointestinal adverse effects of anti-obesity medications in non-diabetic adults: a systematic review","volume":"61","author":"Takrori","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/jcm13216532","article-title":"Effectiveness and safety of GLP-1 receptor agonists in patients with type 1 diabetes","volume":"13","author":"Almohareb","year":"2024","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.15537\/1658-3175.8842","article-title":"Patient experiences and safety concerns regarding GLP-1 receptor agonists for obesity: a cross-sectional survey in Jeddah, Saudi Arabia","volume":"47","author":"Tobaiqy","year":"2026","journal-title":"Saudi Med J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"103796","DOI":"10.1016\/j.eclinm.2026.103796","article-title":"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","volume":"93","author":"Budini","year":"2026","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1918350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:02Z","timestamp":1790144162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1918350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"alternative-id":["10.3389\/fpubh.2026.1918350"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1918350","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1918350"}}